Objectives: Psoriatic arthritis (PsA) is a heterogeneous inflammatory disease in which a significant proportion of patients remain refractory to existing therapies. The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) initiated a project aimed at unravelling the reasons for treatment failures in PsA, culminating in the establishment of definitions for difficult-to-treat PsA (D2T-PsA) and complex-to-manage PsA (C2M-PsA). This study explores patient perspectives on treatment-resistant PsA, incorporating a broader patient perspective into the overarching GRAPPA project. Methods: A multilingual (10 languages), online survey to explore PsA patients' perspectives on treatment inefficacies was used. It was developed collaboratively by GRAPPA members and patient research partners. It included sections on demographic data, structured questions about treatment failures, and open-ended questions. Data analysis used descriptive statistics and inductive coding of qualitative responses via Dedoose. Results: Among 570 respondents, most were female (68.8%) and White (72.6%), with an average PsA diagnosis delay of 4.3 years. Key contributors to D2T- and C2M-PsA were persistent joint pain and psoriasis (65.7%), fatigue (52.8%) and medication side effects (41.7%). Ranked by impact, arthritis was the most debilitating symptom. Quality of life concerns were notable, with sleep impairment and reduced life enjoyment being reported by 66.4%. Language differences emerged; for instance, Dutch and Italian respondents prioritized fatigue and daily life impact, respectively. Conclusion: This is the first international study to highlight patient-driven insights in the management of resistant PsA, emphasizing a multidimensional approach that considers biological and psychosocial factors. These insights will inform the ongoing GRAPPA initiative to standardize definitions for treatment-resistant PsA, ultimately improving patient care.
Dear Editor, The introduction of targeted immune-modulating therapy into the frontline setting has changed the landscape for immune-mediated inflammatory diseases, particularly in the field of dermatology and rheumatology. While substantial progress has been made, the safety profile of currently available therapies is still less than optimal [ 1]. One of the adverse events that has been a topic of interest is the paradoxical cutaneous reactions with immune-modulating therapies. Paradoxical psoriasis (PsO) has been studied in patients on TNF-α inhibitors. Pugliese et al. [ 2] reported that the incidence rate of paradoxical PsO in patients with inflammatory bowel disease was 5/100 person-years and that smoking is the main risk factor for developing these lesions. In addition to TNF-α, several proinflammatory cytokines such as IL-1β, IL-6, IL-8 and IL-17 are implicated in the pathogenesis of autoimmune diseases that fall under the umbrella of spondyloarthritis [ 3]. Karamanakos et al. [ 4] conducted a review and linked paradoxical PsO to multiple biologic therapies that inhibit these pro-inflammatory cytokines. In particular, inhibition of the IL-17 axis has been implicated in the development of these reactions. US Food and Drug Administration–approved monoclonal antibodies that inhibit the IL-17 axis have been divided into three categories: anti-IL-17A inhibitors (secukinumab and ixekizumab), anti-IL-17 receptor A inhibitor (brodalumab) and IL-17A/F inhibitor (bimekizumab). IL-17 inhibitors are very effective in controlling disease activity and have been proven to be superior to TNF inhibitors in several head-to-head PsO trials [ 5]. However, current mechanisms of suppression of the IL-17 axis can lead to complications such as secondary inefficacy due to immunogenicity and the development of IBD. Similar to TNF inhibitors, the cytokine imbalance by inhibition of the IL-17 axis can cause paradoxical PsO [ 6]. Our objective was to review the published data regarding the risk of development of paradoxical PsO in patients on IL-17 inhibitors.
Psoriatic arthritis (PsA) is a complex, heterogeneous disease affecting multiple domains which necessitates a nuanced approach to treatment. While tumor necrosis factor (TNF) inhibitors have historically been the preferred first line therapy, increasing evidence highlights the efficacy of interleukin (IL) 17 and IL-23 inhibitors, particularly in cases of nonresponse to TNF inhibitors. These targeted biologics offer additional therapeutic options, especially for those with concomitant psoriasis (PsO) and axial disease. The proposed biologic sequence derived from clinical trial data and expert opinion incorporates PsA disease severity as well as concomitant PsO and axial disease in the setting of biologic nonresponse. This approach aims to guide clinicians in selecting the most effective therapy while conserving future treatment options. However, gaps remain in understanding the sequential use of IL-17 and IL-23 inhibitors, particularly in axial disease, emphasizing the need for further research and real-world clinical data.
The interplay between metabolic health and autoimmune diseases such as psoriasis (PsO) and psoriatic arthritis (PsA) has garnered increasing attention. Obesity, a key feature of metabolic syndrome, exacerbates disease severity in these conditions, prompting the exploration of treatments addressing both the immune system and metabolism. Glucagon-like peptide 1 receptor agonists (GLP-1RAs), primarily used for type 2 diabetes mellitus, have demonstrated benefits beyond glycemic control, including promoting weight loss, improving metabolic health, and potentially modulating immune responses. There is also a dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonist with similar and potentially superior capabilities; throughout this manuscript these will be collectively known as GLP-1RA. Recent studies also suggest that GLP-1RAs may help manage PsO and PsA in patients with obesity. These medications may offer dual benefits by reducing inflammation and addressing metabolic abnormalities like insulin resistance and hyperlipidemia. This article reports on a presentation given at the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2024 annual meeting underscoring the potential of GLP-1RAs as a therapeutic option, particularly for obese patients with PsO and PsA. Although promising, the evidence supporting GLP-1RAs for treating PsO and PsA remains limited, necessitating further clinical research to evaluate their safety and efficacy.